• Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial
• The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year
• The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with diabetes and cancer, recently disclosed favorable preliminary clinical data from the Phase 1 portion of its Acclaim-1 clinical trial. During the study, Genprex’s lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities. In addition, the company reported preliminary evidence of efficacy in the phase 1 portion of the study.

“We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed. These data supported the Safety Review Committee’s approval to advance to the Phase 2 expansion portion of the clinical trial which we expect to begin in the third quarter,” said Mark Berger, MD, Chief Medical Officer at Genprex (https://ibn.fm/miTxk).

The Phase 1 clinical data were added to by the recent release of a new patient video featuring a non-small cell lung cancer (“NSCLC”) patient from the Phase 1 portion of the study. The patient highlighted in the video achieved a Partial Response and experienced extended Progression Free Survival (“PFS”). She described her positive experience taking REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year.

The patient’s positive experience has been described as encouraging, mainly because she could continue working full-time while participating in the clinical trial. She only experienced minor side effects from using the lead drug candidate. This is particularly significant since NSCLC is ranked as the most common type of lung cancer, accounting for about 82% of all cases. In addition, the overall survival rate for patients with advanced levels of the condition is alarmingly low, with a five-year survival rate for patients with distant spread standing at 7% (https://ibn.fm/85dk7).

“While on REQORSA treatment, my doctor noted that the lung cancer lesions have not grown, and there is no new growth,” noted the NSCLC patient.

“I believe the REQORSA treatment has benefited my life and has increased my time,” she added.

The Safety Review Committee (“SRC”) noted that there were no Dose Limiting Toxcities (“DLTs”) during the Phase 1 trial and approved the advancement of the Acclaim-1 clinical trial to the Phase 2 expansion portion of the trial. The approval is a significant milestone in REQORSA’s development program, and now positions REQORSA as a Phase 2 clinical trial asset.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]